CMS launched a voluntary payment model designed to expand Medicare coverage for GLP‑1 weight‑loss drugs. The agency invited plans and providers to participate in a pilot that alters payment and coverage mechanics for these branded biologics, aiming to improve beneficiary access while testing cost‑control measures. The announcement frames the model as voluntary but consequential: participating Medicare plans would adopt new reimbursement structures that could reduce out‑of‑pocket cost barriers for seniors. CMS cited the rapid uptake and high prices of GLP‑1s as drivers of the policy experiment. Industry participants will be watching enrollment signals and any pricing concessions that emerge during the pilot.